Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Plaque Psoriasis Management: Evaluating Non-Steroidal Treatments and Current Data Trends : Episode 6

Opinion

Video

July 11, 2024

Head-to-Head Clinical Trials: Comparing Psoriasis Treatment Response Rates

Author(s):

Alexa Hetzel, MS, PA-C,Andrew Mastro, MS, PA-C

This professional summary discusses the definitions of loss of response and loss of efficacy in patient therapy, while also comparing response rates across different psoriasis treatments.

EP: 1.Navigating Plaque Psoriasis: Insights into the Psychosocial Impact and Evolving Treatment Landscape

EP: 2.Plaque Psoriasis Case Study: Patient Presentation, Treatment Selection, and Shared Decision-Making for Improved Outcomes

EP: 3.Empowering Patients with Plaque Psoriasis: Navigating Treatment Challenges Informed Patient Conversations and Decision Trees

EP: 4.A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

EP: 5.Clinical Insights: Managing Psoriasis Treatment Dynamics and Strategic Therapy Switching Considerations

Now Viewing

EP: 6.Head-to-Head Clinical Trials: Comparing Psoriasis Treatment Response Rates

EP: 7.TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations

EP: 8.Comparative Analysis: Deucravacitinib and Adalimumab in Psoriasis Treatment

EP: 9.Understanding IL-17 Therapies: Treatment Considerations, Rapid Response, and Impact on Plaque Psoriasis Location

EP: 10.Expert Insights into Managing Inadequate Response to Systemic Therapies: Strategies and Solutions

EP: 11.Long-Term Efficacy and Insights from POETYK PSO-1 Studies: Implications for Psoriasis Treatment

EP: 12.Achieving Durable Responses: Physician's Guide to Interpreting Long-Term Efficacy Data

EP: 13.When to Discontinue Treatment: Interpreting Safety Signals and Adverse Event Patterns

EP: 14.Updating Treatment Guidelines: Incorporating Novel Therapies to Address Unmet Needs

EP: 15.Available Psoriasis, Patient Involvement, and Holistic Treatment

Related Content

January 20th 2025

Secukinumab Demonstrates Long-Term Safety and Efficacy in Pediatric Patients with GPP

November 4th 2021

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

$Psoriasis Resolution in a Patient Treated With CD19 CAR T-Cell Therapy for Refractory DLBCL$

January 15th 2025

Psoriasis Resolution in a Patient Treated With CD19 CAR T-Cell Therapy for Refractory DLBCL

September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

December 26th 2024

Dermatology Times 2024 in Review: Psoriasis

December 18th 2024

Fighting the Flare of GPP: Expert Insights on Spesolimab

About

Advertise

Job Board

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777